Novavax Inc (NVAX)
8.05
-0.01
(-0.12%)
USD |
NASDAQ |
Nov 21, 16:00
7.95
-0.10
(-1.24%)
After-Hours: 20:00
Novavax Revenue (Quarterly): 84.51M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 84.51M |
| June 30, 2024 | 415.48M |
| March 31, 2024 | 93.86M |
| December 31, 2023 | 253.40M |
| September 30, 2023 | 22.06M |
| June 30, 2023 | 424.43M |
| March 31, 2023 | -6.428M |
| December 31, 2022 | 287.83M |
| September 30, 2022 | 628.30M |
| June 30, 2022 | 185.92M |
| March 31, 2022 | 604.67M |
| December 31, 2021 | -726.51M |
| September 30, 2021 | 178.84M |
| June 30, 2021 | 298.02M |
| March 31, 2021 | 447.23M |
| December 31, 2020 | -173.55M |
| September 30, 2020 | 157.02M |
| June 30, 2020 | 35.54M |
| March 31, 2020 | 3.377M |
| December 31, 2019 | 8.816M |
| September 30, 2019 | 2.507M |
| June 30, 2019 | 3.357M |
| March 31, 2019 | 3.982M |
| December 31, 2018 | 6.127M |
| September 30, 2018 | 7.735M |
| Date | Value |
|---|---|
| June 30, 2018 | 10.77M |
| March 31, 2018 | 9.653M |
| December 31, 2017 | 10.41M |
| September 30, 2017 | 8.352M |
| June 30, 2017 | 6.732M |
| March 31, 2017 | 5.68M |
| December 31, 2016 | 5.399M |
| September 30, 2016 | 3.231M |
| June 30, 2016 | 2.505M |
| March 31, 2016 | 4.218M |
| December 31, 2015 | 5.853M |
| September 30, 2015 | 6.525M |
| June 30, 2015 | 14.00M |
| March 31, 2015 | 9.877M |
| December 31, 2014 | 6.724M |
| September 30, 2014 | 8.214M |
| June 30, 2014 | 8.259M |
| March 31, 2014 | 7.462M |
| December 31, 2013 | 8.748M |
| September 30, 2013 | 4.802M |
| June 30, 2013 | 3.531M |
| March 31, 2013 | 3.833M |
| December 31, 2012 | 4.566M |
| September 30, 2012 | 5.765M |
| June 30, 2012 | 7.103M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
-726.51M
Minimum
Dec 2021
628.30M
Maximum
Sep 2022
161.14M
Average
167.93M
Median
Revenue (Quarterly) Benchmarks
| Pfizer Inc | 17.70B |
| Moderna Inc | 1.855B |
| Inovio Pharmaceuticals Inc | -- |
| Baxter International Inc | 2.699B |
| Halozyme Therapeutics Inc | 290.08M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -121.30M |
| Total Expenses (Quarterly) | 218.53M |
| EPS Diluted (Quarterly) | -0.76 |
| Enterprise Value | 550.83M |
| Gross Profit Margin (Quarterly) | 28.27% |
| Profit Margin (Quarterly) | -143.5% |
| Earnings Yield | -28.45% |
| Normalized Earnings Yield | -28.45 |